Andrew Slatter

This inventor holds 14 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Illumina Cambridge Limited, Illumina Corporation. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Slatter. Retrieved from https://idiyas.com/inventor/andrew-slatter-6vl5sqhv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 10 (Patent Applications = 27)

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 38(Granted Patents)

Location History:

Saffron Walden, GB (2021)
Cambridge, GB (2020 - 2023)

Company Filing History:

13 out of 323

Illumina Cambridge Limited

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692535 - METHODS OF ENRICHING A TARGET SEQUENCE FROM A SEQUENCING LIBRARY USING HAIRPIN ADAPTORS (2026-07-28),

2. 12534718 - Separating polynucleotide fragments (2026-01-27),

3. 12448644 - Complex surface-bound transposome complexes (2025-10-21),

4. 12435362 - Compositions and methods for improving library enrichment (2025-10-07),

5. 12234451 - Tagmentation using immobilized transposomes with linkers (2025-02-25),

6. 12188078 - Methods for preparing a sample for nucleic acid amplification using tagmentation (2025-01-07),

7. 11760994 - Separating polynucleotide fragments (2023-09-19),

8. 11714848 - Time-based cluster imaging of amplified contiguity-preserved library fragments of genomic DNA (2023-08-01),

9. 11708573 - Tagmentation using immobilized transposomes with linkers (2023-07-25),

10. 11685946 - Complex surface-bound transposome complexes (2023-06-27),

11. 11306348 - Complex surface-bound transposome complexes (2022-04-19),

12. 11142786 - Methods for preparing a sample for nucleic acid amplification using tagmentation (2021-10-12),

13. 10920219 - Tagmentation using immobilized transposomes with linkers (2021-02-16),

14. 10774367 - Methods for preparing a sample for nucleic acid amplification using tagmentation (2020-09-15),

Title: The Innovations of Andrew Slatter: A Pioneering Inventor in Nucleic Acid Technologies

Introduction

Andrew Slatter, based in Cambridge, GB, is a distinguished inventor known for his contributions to nucleic acid technologies. With a remarkable portfolio of 10 patents, Slatter's work has significantly advanced the fields of molecular biology and genetic research.

Latest Patents

Among his latest patents are two groundbreaking inventions. The first, titled "Tagmentation using immobilized transposomes with linkers," focuses on methods, compositions, and kits for treating target nucleic acids. This invention covers innovative techniques for fragmenting and tagging nucleic acids, such as DNA, utilizing transposome complexes bound to solid supports. The second patent, "Methods for preparing a sample for nucleic acid amplification using tagmentation," outlines efficient processes for preparing samples for amplification and sequencing. These methods include lysing cells to create a lysate, amplifying nucleic acids without prior purification, and sequencing from samples, including blood and formalin-fixed paraffin-embedded (FFPE) samples.

Career Highlights

Andrew Slatter has made substantial strides in his career, notably working with Illumina Cambridge Limited and Illumina Corporation. His experiences in these innovative companies have allowed him to contribute to the development of cutting-edge technologies in genomics and biotechnology.

Collaborations

Throughout his career, Slatter has collaborated with talented individuals, including coworkers Natalie Morrell and Louise Fraser. Their collective expertise has fostered a dynamic research environment that has led to significant advancements in their field.

Conclusion

Andrew Slatter's inventive spirit and dedication to enhancing nucleic acid technologies position him as a prominent figure in the research community. As he continues to innovate and develop new methods and compositions, the impact of his work will undoubtedly resonate within the fields of molecular biology and genetics for years to come.

Profile summary based on public USPTO records.